The European Commission announces the marketing of the first vaccine against bronchiolitis, to be administered to pregnant women.
The European Commission announced Friday evening that it authorized the marketing of Abrysvo, the vaccine of the pharmaceutical giant Pfizer against bronchiolitis in infants and people over 60 years of age. The European Medicines Agency had approved it in July.
The vaccine, administered to pregnant women, targets the highly contagious respiratory syncytial virus (RSV), which causes thousands of deaths and hundreds of thousands of hospitalizations worldwide, causing bronchiolitis and pneumonia.
In addition, a preventive treatment jointly developed by AstraZeneca and Sanofi, called Beyfortus and intended for infants, has recently been authorized in Europe and the United States.
This article is originally published on radio1.pf
